MYC and neoplasm: The disruption of the CoREST-MYC-NOLC1 pathway actively promotes these aberrant splicing events, which not only suppress tumor growth but also produce novel, immunogenic splice-neoantigens capable of triggering anti-tumor immune responses [55,56,57].